The BASIS study was a phase 3, open-label, multicenter study that aimed to test the efficacy of marstacimab in patients with severe hemophilia of factor VIII activity of less than 1% or moderately ...

Most people with moderate to severe hemophilia B depend on weekly life-long prophylactic infusions of factor IX, which temporarily replaces or supplements low levels of the blood-clotting factor.

More information: Ulrike M. Reiss et al, Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B, New England Journal of Medicine (2025). DOI: 10.1056/NEJMoa2414783 ...

Pfizer Inc. (NYSE:PFE) ranks among the best set-it-and-forget-it stocks to buy. On June 26, Pfizer Inc. (NYSE:PFE) declared that the Phase 3 BASIS research results showed that its medication ...

Topline data were announced from a phase 3 trial evaluating marstacimab for adults and adolescents living with hemophilia A or B with inhibitors. Marstacimab is a tissue factor pathway inhibitor ...

Capital City Squares in Sacramento promotes LGBTQ+ inclusion through square dancing. The group, which has more than 100 members, meets at Fruitridge Community Center.

Well-Tolerated Switch to Mim8: Phase IIIb FRONTIER5 trial shows patients with hemophilia A can safely switch from Hemlibra (emicizumab) to Mim8 without a washout period or loading dose. Strong Patient ...

Hympavzi cut annualized bleeding rate by 93% vs. on-demand care in hemophilia patients with inhibitors. The 12-month Phase 3 BASIS trial reported no deaths or thromboembolic events. Market-moving ...

According to the Centers for Disease Control and Prevention, there are approximately 33,000 males living with hemophilia in the United States. Close to 70% of all cases are diagnosed in infants ...

Pfizer on Thursday said the Phase 3 study of Hympavzi in patients 12 and older with hemophilia A or B with inhibitors met its primary endpoint and key secondary bleeding endpoints, showing a ...

NEW YORK, June 26, 2025--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI™ (marstacimab) for adults and adolescents ...

Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments ineffective.